Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ALXN2220 · 3 trials · 3 indications
To evaluate the long-term safety and tolerability of ALXN2220 in participants with ATTR-CM
| Arm | Type | Description |
|---|---|---|
| ALXN2220 | EXPERIMENTAL | Eligible participants will receive ALXN2220 administered IV q4w for a minimum of 12 months and up to 24 months or until participant has access to commercially available ALXN2220 for ATTR-CM, whichever occurs first. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive placebo via IV infusion q4w for at least 30 months up to a maximum of 48 months. |
| Name | Type | Description |
|---|---|---|
| ALXN2220 | DRUG | To be administered as an IV infusion |
| Placebo | DRUG | Participants will receive placebo via IV infusion. |
* Inclusion Criteria * Type of Participant: Participants who have completed the Blinded Treatment Period (including the PC visit) of Study 301. * Sex and Contraceptive/Barrier Requirements: Male and/or female (according to their reproductive organs and functions assigned by chromosomal complement). ...
ALXN2220 is being developed for the treatment of amyloid transthyretin cardiomyopathy, also called transthyretin amyloid cardiomyopathy or ATTR-CM. It is an investigational small molecule therapeutic being studied in adults with this cardiovascular condition. ALXN2220 has not been approved for any indication and remains in clinical development.
ALXN2220 is being developed by AstraZeneca PLC, which trades on the Nasdaq under the ticker AZN. AstraZeneca is the sponsor of the clinical program evaluating ALXN2220 in adults with transthyretin amyloid cardiomyopathy.
ALXN2220 is in Phase 3 clinical development for transthyretin amyloid cardiomyopathy. The program includes two Phase 3 studies and one Phase 2 study, with a total planned enrollment of approximately 2,396 participants across the trials. ALXN2220 is investigational and has not been approved by the FDA.
ALXN2220 is being evaluated in three registered trials. NCT06183931 is a Phase 3 placebo-controlled study of ALXN2220 versus placebo in adults with ATTR-CM. NCT07789483 is a Phase 3 open-label long-term safety and efficacy study. NCT07213583 is a Phase 2 re-treatment study in patients with ATTR-CM.
Yes. The Phase 3 study NCT06183931 is a randomized, double-blind, placebo-controlled trial of ALXN2220 in adults with transthyretin amyloid cardiomyopathy. That trial has a planned enrollment of 1,181 participants and is currently active but not recruiting. The other Phase 3 trial, NCT07789483, is an open-label long-term safety and efficacy study.
ALXN2220 trials are running across many countries, including the United States, Canada, Brazil, Argentina, the United Kingdom, France, Germany, Spain, Italy, the Netherlands, Japan, China, South Korea, Australia, and others. The Phase 3 studies enroll adults with transthyretin amyloid cardiomyopathy, and the Phase 2 re-treatment study runs in France, Germany, the Netherlands, and Spain.